{"id":"NCT01946412","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation","officialTitle":"A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2013-09-19","resultsPosted":"2017-02-01","lastUpdate":"2017-02-01"},"enrollment":33,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770","Kalydeco"]}],"arms":[{"label":"Observational Arm","type":"NO_INTERVENTION"},{"label":"Ivacaftor","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with Cystic Fibrosis (CF) who have a CFTR gating mutation in at least 1 allele and will further explore the efficacy of long-term ivacaftor treatment in this population of patients with CF.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)","effectByArm":[{"arm":"Ivacaftor 50 mg","deltaMin":9,"sd":null},{"arm":"Ivacaftor 75 mg","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States","Canada","United Kingdom"]},"refs":{"pmids":["31053538"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":9},"commonTop":["Cough","Vomiting","Pyrexia","Nasal congestion","Otitis media"]}}